[go: up one dir, main page]

SV2016005353A - Forma polimã“rfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi) bencilamina para el tratamiento del alzhã‰imer - Google Patents

Forma polimã“rfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi) bencilamina para el tratamiento del alzhã‰imer

Info

Publication number
SV2016005353A
SV2016005353A SV2016005353A SV2016005353A SV2016005353A SV 2016005353 A SV2016005353 A SV 2016005353A SV 2016005353 A SV2016005353 A SV 2016005353A SV 2016005353 A SV2016005353 A SV 2016005353A SV 2016005353 A SV2016005353 A SV 2016005353A
Authority
SV
El Salvador
Prior art keywords
tetrafluoropropoxi
bencilamine
novedous
etil
indol
Prior art date
Application number
SV2016005353A
Other languages
English (en)
Inventor
Kristine Birklund Andersen
Michael Harold Rock
De Diego Heidi Lopez
Frans Dennis Therkelsen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58794010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2016005353(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SV2016005353A publication Critical patent/SV2016005353A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA FORMA POLIMÓRFICA NOVEDOSA DEL CLORHIDRATO DE N-[2-(6-FLUORO-1H-INDOL-3-IL) ETIL] -3- (2,2,3,3-TETRAFLUOROPROPOXI) BENCILAMINA
SV2016005353A 2014-07-04 2016-12-22 Forma polimã“rfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi) bencilamina para el tratamiento del alzhã‰imer SV2016005353A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400369 2014-07-04
PCT/EP2015/065176 WO2016001398A1 (en) 2014-07-04 2015-07-03 Novel polymorphic form of n-[2-(6-fluoro-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer's

Publications (1)

Publication Number Publication Date
SV2016005353A true SV2016005353A (es) 2017-03-23

Family

ID=58794010

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2016005353A SV2016005353A (es) 2014-07-04 2016-12-22 Forma polimã“rfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi) bencilamina para el tratamiento del alzhã‰imer

Country Status (42)

Country Link
US (1) US10071963B2 (es)
EP (1) EP3164385B1 (es)
JP (2) JP6643330B2 (es)
KR (1) KR102399374B1 (es)
CN (3) CN112961095A (es)
AP (1) AP2016009643A0 (es)
AR (1) AR101109A1 (es)
AU (1) AU2015282909B2 (es)
CA (1) CA2951794C (es)
CL (1) CL2017000002A1 (es)
CO (1) CO2017000019A2 (es)
CR (1) CR20160605A (es)
CY (1) CY1124594T1 (es)
DK (1) DK3164385T3 (es)
DO (1) DOP2017000001A (es)
EA (1) EA035894B1 (es)
EC (1) ECSP17000222A (es)
ES (1) ES2893619T3 (es)
GE (1) GEP20227368B (es)
HR (1) HRP20211596T8 (es)
HU (1) HUE056368T2 (es)
IL (1) IL249428B (es)
JO (1) JO3639B1 (es)
LT (1) LT3164385T (es)
MA (1) MA40345B1 (es)
MX (1) MX377013B (es)
MY (1) MY190715A (es)
NZ (1) NZ727251A (es)
PE (1) PE20170522A1 (es)
PH (1) PH12016502477B1 (es)
PL (1) PL3164385T3 (es)
PT (1) PT3164385T (es)
RS (1) RS62380B1 (es)
RU (1) RU2016151637A (es)
SG (1) SG11201610334XA (es)
SI (1) SI3164385T1 (es)
SM (1) SMT202100575T1 (es)
SV (1) SV2016005353A (es)
TN (1) TN2016000549A1 (es)
TW (1) TWI665188B (es)
UA (1) UA121547C2 (es)
WO (1) WO2016001398A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333154A1 (en) 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1379239T3 (da) 2001-03-29 2008-01-07 Lilly Co Eli N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
TW201139370A (en) * 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN105175307A (zh) 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途

Also Published As

Publication number Publication date
CA2951794C (en) 2023-03-07
MY190715A (en) 2022-05-12
MA40345A (fr) 2021-04-28
ECSP17000222A (es) 2017-02-24
SG11201610334XA (en) 2017-01-27
US20170152227A1 (en) 2017-06-01
JP2020059724A (ja) 2020-04-16
JP2017519829A (ja) 2017-07-20
EP3164385A1 (en) 2017-05-10
KR102399374B1 (ko) 2022-05-17
JP6643330B2 (ja) 2020-02-12
DOP2017000001A (es) 2017-03-31
NZ727251A (en) 2023-06-30
CY1124594T1 (el) 2022-07-22
AR101109A1 (es) 2016-11-23
PE20170522A1 (es) 2017-05-28
WO2016001398A1 (en) 2016-01-07
RU2016151637A (ru) 2018-08-08
CN106458889A (zh) 2017-02-22
PL3164385T3 (pl) 2021-12-20
US10071963B2 (en) 2018-09-11
SI3164385T1 (sl) 2021-10-29
LT3164385T (lt) 2021-10-11
SMT202100575T1 (it) 2021-11-12
CN112961094A (zh) 2021-06-15
TW201625525A (zh) 2016-07-16
PT3164385T (pt) 2021-10-07
AU2015282909A1 (en) 2017-01-05
CO2017000019A2 (es) 2017-05-31
EP3164385B1 (en) 2021-09-08
CL2017000002A1 (es) 2017-06-23
HUE056368T2 (hu) 2022-02-28
DK3164385T3 (da) 2021-10-11
GEP20227368B (en) 2022-03-25
PH12016502477A1 (en) 2017-04-10
JO3639B1 (ar) 2020-08-27
CR20160605A (es) 2017-04-24
AU2015282909B2 (en) 2019-02-07
IL249428A0 (en) 2017-02-28
CA2951794A1 (en) 2016-01-07
CN112961095A (zh) 2021-06-15
TN2016000549A1 (en) 2018-04-04
RU2016151637A3 (es) 2019-01-28
PH12016502477B1 (en) 2017-04-10
HRP20211596T8 (hr) 2022-03-04
AP2016009643A0 (en) 2016-12-31
UA121547C2 (uk) 2020-06-25
BR112017000127A2 (pt) 2018-01-23
IL249428B (en) 2019-10-31
KR20170023019A (ko) 2017-03-02
HRP20211596T1 (hr) 2022-01-07
ES2893619T3 (es) 2022-02-09
MA40345B1 (fr) 2021-10-29
TWI665188B (zh) 2019-07-11
RS62380B1 (sr) 2021-10-29
MX2016016895A (es) 2017-04-27
MX377013B (es) 2025-03-07
EA201692485A1 (ru) 2017-05-31
EA035894B1 (ru) 2020-08-27

Similar Documents

Publication Publication Date Title
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
PL3139925T3 (pl) Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
UY34780A (es) Vectores virales para el tratamiento de distrofia retiniana
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
CY1122264T1 (el) Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
EA201791174A1 (ru) Антимикотическое соединение
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX386458B (es) Composiciones de péptidos t inmuno-terapéuticas para usarse en el tratamiento de metástasis cerebrales.
ES1192835Y (es) Maquina para el despedregado del terreno
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
CR20160226A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
TR201819920T4 (tr) Kuru göz sendromunun tedavisinde kullanım için oftalmik bileşimler.
SV2016005353A (es) Forma polimã“rfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi) bencilamina para el tratamiento del alzhã‰imer
HUE036206T2 (hu) N,N-bisz-2-merkaptoetil-izoftálamid új alkalmazása
BR112016030966A2 (pt) fonte de evaporação de arco